Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
Portfolio Pulse from
Halozyme Therapeutics (HALO) reported Q4 earnings of $1.26 per share, surpassing the Zacks Consensus Estimate of $1.16. This marks an increase from $0.82 per share a year ago.
February 18, 2025 | 11:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Halozyme Therapeutics reported Q4 earnings of $1.26 per share, exceeding expectations and showing growth from the previous year.
The company's earnings per share exceeded analyst expectations and showed significant growth compared to the previous year, which is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100